Mallinckrodt PLC

Mallinckrodt Plc engages in the development, manufacture, market, adn distribution of both branded and generic specialty pharmaceutical products and medical imaging agents. It operates through the Specialty Brands and Specialty Generics segments. The Specialty Brands segment includes innovative specialty pharmaceutical brands. The Specialty Generics segment relates to niche specialty generic drugs and active pharmaceutical ingredients. The company was founded by Gustavo Mallinckrodt, Otto Mallinckrodt and Edward Mallinckrodt in 1867 and is headquartered in Blanchardstown, Dublin.

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DUBLIN , Oct. 10, 2023 /PRNewswire/ -- Mallinckrodt plc (in examinership) (OTCMKTS: MNKTQ) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that its Plan of Reorganization (the "Plan") has been confirmed by the U.S. Bankruptcy Court for the District of Delaware, positioning the Company to emerge from Chapter 11 by the end of the year. Siggi Olafsson, President and Chief Executive Officer of Mallinckrodt, said, "We are pleased to achieve this important milestone and look forward to moving ahead as a stronger company.

Mallinckrodt plc (in examinership) Receives U.S. Court Approval for Financial Restructuring Plan

DUBLIN , Aug. 31, 2023 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKTQ), a global specialty pharmaceutical company, today announced that its Specialty Generics segment, operating as SpecGx LLC, received approval on August 25, 2023 from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application for Lisdexamfetamine Dimesylate Capsules 10mg, 20mg, 30mg, 40mg, 50mg, 60mg, and 70mg. The FDA determined SpecGx LLC's product was bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Vyvanse® Capsules of Takeda Pharmaceuticals U.S.A.

Mallinckrodt Receives U.S. FDA Approval for Lisdexamfetamine Dimesylate Capsules and Launches Product Used to Treat Attention-Deficit/Hyperactivity Disorder (ADHD)

LOS ANGELES , Aug. 30, 2023 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Mallinckrodt plc ("Mallinckrodt" or the "Company") (NYSE: MNK).

MNK Investors Have Opportunity to Lead Mallinckrodt plc Securities Fraud Lawsuit

Continuing to Serve Customers and Deliver High-Quality Therapies to Patients Without Interruption; Vendors and Suppliers to be Paid in Full in the Ordinary Course DUBLIN , Aug. 30, 2023 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKTQ) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that it has received approvals from the U.S. Bankruptcy Court for the District of Delaware for its "First Day" motions related to the Company's voluntary Chapter 11 petitions filed on August 28, 2023. As expected, the Court granted Mallinckrodt approval to access $150 million of the $250 million of commitments for new financing it received from certain of its creditors, as well as new borrowing availability from lenders under its asset-based loans.

Mallinckrodt Receives Court Approval for "First Day" Motions to Support Ongoing Operations

NEW YORK--(BUSINESS WIRE)--NYSE American LLC (“NYSE American” or the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the Ordinary Shares of Mallinckrodt plc (the “Company”) — ticker symbol MNK — from NYSE American. Trading in the Company's Ordinary Shares will be suspended immediately. NYSE Regulation has determined that the Company is no longer suitable for listing and will commence delisting proceedings pursuant to Section 1003(c).

NYSE American to Commence Delisting Proceedings Against Mallinckrodt plc (MNK)

NEW YORK , Aug. 28, 2023 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Mallinckrodt plc ("Mallinckrodt" or the "Company") (NYSE: MNK), and certain officers.   The class action, filed in the United States District Court for the District of New Jersey, and docketed under 23-cv-03662, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Mallinckrodt securities between June 17, 2022 and June 14, 2023, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 ("Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Mallinckrodt plc of Class Action Lawsuit and Upcoming Deadline - MNK

Mallinckrodt PLC (NYSE:MNK) stock tumbled a further 15% after the pharmaceutical company confirmed it had initiated voluntary prepackaged Chapter 11 proceedings in the Delaware Bankruptcy Court, just over a year after coming out of a previous bankruptcy. Under a Restructuring Support Agreement (RSA) reached with a substantial majority of its debtholders and the Opioid Master Disbursement Trust II, the company said it expects to complete the court-supervised process in the fourth quarter of 2023.

Mallinckrodt shares continued to tumble as it files for Chapter 11 bankruptcy

Mallinckrodt PLC made it official Monday, with the Dublin, Ireland-based drugmaker filing for bankruptcy for the second time in three years after struggling to make settlement payments for its role in the opioid crisis.

Mallinckrodt discloses grand jury subpoena, makes bankruptcy filing official

Drugmaker Mallinckrodt on Monday said the company and some of its units have filed for a second bankruptcy in 3 years in the U.S., with the newest restructuring plan set to reduce its debt by about $1.9 billion.

Drugmaker Mallinckrodt files for second bankruptcy in the US

Initiates Voluntary Prepackaged Chapter 11 Proceedings with Overwhelming Support of Key Stakeholders, Including 85%+ of First and Second Lien Debtholders Continuing to Operate Normally, Serve Customers and Deliver High-Quality Therapies to Patients Vendors and Suppliers Expected to be Paid in Full in the Ordinary Course DUBLIN , Aug. 28, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE American: MNK) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that it has taken the next step to implement the comprehensive financial restructuring plan contemplated by a Restructuring Support Agreement ("RSA") the Company previously entered into with more than 85% of each of the Company's first and second lien debtholders and the Opioid Master Disbursement Trust II (the "Trust"), as announced on August 23, 2023. Pursuant to the RSA and with the authorization of the Company's Board of Directors, Mallinckrodt and certain of its subsidiaries 1  today initiated voluntary prepackaged Chapter 11 proceedings in the U.S. Bankruptcy Court for the District of Delaware.

Mallinckrodt plc Takes Next Step to Implement Comprehensive Financial Restructuring Plan to Address Long-Term Debt and Opioid Obligations

NEW YORK , Aug. 26, 2023 /PRNewswire/ --Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Mallinckrodt plc ("Mallinckrodt" or the "Company") (NYSE: MNK) and reminds investors of the September 5, 2023 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $100,000 investing in Mallinckrodt stock or options between June 17, 2022 and June 14, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext.

MALLINCKRODT SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Mallinckrodt To Contact Him Directly To Discuss Their Options

Mallinckrodt PLC (NYSE:MNK) said it plans to initiate voluntary prepackaged Chapter 11 bankruptcy proceedings in the US in a matter of days to give it room to restructure its debt and reduce the amount it owes to opioid victims. Its shares fell 18% to $0.48 shortly before midday in New York, taking their year-to-date loss to 94%.

Mallinckrodt stock tumbles on plans to file for Chapter 11 bankruptcy for second time in three years

Mallinckrodt (NYSEMKT: MNK ) stock isn't doing so hot on Wednesday after the pharmaceutical company gets ready for another bankruptcy filing. A press release from Mallinckrodt notes that it's going to file for bankruptcy in the coming days.

MNK Stock Alert: Mallinckrodt Files for Bankruptcy Again

Mallinckrodt is planning to start bankruptcy proceedings in the coming days, the U.S. drugmaker said on Wednesday, as it struggles to make required settlement payments for lawsuits alleging that it helped fuel the U.S. opioid crisis.

U.S. drugmaker Mallinckrodt plans to file for bankruptcy protection

Mallinckrodt PLC MNK, +5.09% said Wednesday it has entered a Restructuring Support Agreement with most of its first and second lien debtholders and the Opioid Master Disbursement Trust II on the terms of a restructuring that will see it reduce its debt by about $1.9 billion. The agreement includes a final payment of $250 million to the Trust, on top of the $450 million already paid, to support its work on the opioid crisis and to fund addiction programs.

Mallinckrodt to file for prepackaged Chapter 11 bankruptcy and cut about $1.9 billion in debt

Agreement Supported by a Substantial Majority of Each of its First and Second Lien Debtholders and Opioid Trust Financial Restructuring Plan to Significantly Reduce Debt, Increase Free Cash Flow Generation, Extend Maturity Runway and Better Position Company for Long-Term Success  Intends to Initiate Voluntary Prepackaged Chapter 11 Proceedings to Implement Plan Continuing to Deliver High-Quality Therapies to Patients and Serve Customers; Vendors and Suppliers to be Paid in Full in the Ordinary Course DUBLIN , Aug. 23, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE American: MNK) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced it has entered into a Restructuring Support Agreement ("RSA") with a substantial majority of each of the Company's first and second lien debtholders and the Opioid Master Disbursement Trust II (the "Trust") on the terms of a comprehensive financial restructuring plan that will reduce the Company's total funded debt by approximately $1.9 billion, increase free cash flow generation, extend maturity runway and better position the business for long-term success. The RSA also provides for, among other consideration, a final payment of $250 million to the Trust, in addition to the $450 million previously paid, to support the Trust's mission to address the U.S. opioid crisis and fund addiction treatment.

Mallinckrodt plc Enters into Restructuring Support Agreement with Key Stakeholders on the Terms of a Prepackaged Financial Restructuring Plan

NEW YORK--(BUSINESS WIRE)--The Buxton Helmsley Group, Inc. (together with certain of its affiliates, “BHG” or “we”), the New York City-based investment advisor to clients with financial interests in Mallinckrodt Plc. (“Mallinckrodt” or the “Company”) (NYSE: MNK), today issued an open letter (the “Letter”) to the Company's Board of Directors, regarding the Company's continued failure to make required write-downs of asset values where expenses are evidenced, in apparent violation of GAAP ASC 350/.

Buxton Helmsley Issues Letter to Mallinckrodt Plc. Directors Regarding Bankruptcy Negotiations and Financial Disclosure Violations

Reports Second Quarter Net Sales of $475.0 Million, Reflecting a 1.3% Growth on a Reported and Constant Currency Basis Compared to the Prior Year Quarter Reports Net Loss of $747.8 Million; Adjusted EBITDA of $144.0 Million; Cash on Hand of $480.6 Million at Second Quarter End Reaffirms 2023 Net Sales and Adjusted EBITDA Guidance Terlivaz® Launch Exceeds Expectations, Obtaining Approximately 50% of Targeted Hospital Formulary Access With Continued Medical Community Interest Provides Update on Liquidity and Discussions With Creditors and Opioid Disbursement Trust DUBLIN , Aug. 9, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE American: MNK) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today reported results for the second quarter ended June 30, 2023.1 "Mallinckrodt continued to advance our strategic initiatives in the second quarter, delivering results in line with our expectations. I am particularly pleased to share that we achieved year-over-year revenue growth this quarter – an important step forward in our goal to stabilize the business in the near term and return to sustainable growth in the long term," said Siggi Olafsson, President and Chief Executive Officer.

Mallinckrodt plc Reports Second Quarter 2023 Financial Results and Reaffirms Full Year Guidance

AERWINS Technologies Inc

Tupperware

2023 has unfolded as a pivotal year for investors and traders alike, specifically those keen on harnessing the potential of penny stocks. These stocks, often priced below $5, present unique opportunities and advantages in the world of finance.

Should You Buy Penny Stocks Right Now? 3 Reasons

Drugmaker Mallinckrodt is talking to hedge funds about filing for bankruptcy and avoiding payments intended to help people addicted to opioids, the Wall Street Journal reported on Wednesday.

Drugmaker Mallinckrodt in talks with hedge funds to avoid opioid settlements - WSJ

Drugmaker Mallinckrodt is talking to hedge funds about filing for bankruptcy and avoiding payments intended to help people addicted to opioids.

Hedge Funds Seek to Cut Off $1 Billion Meant for Opioid Victims

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming September 5, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Mallinckrodt plc (“Mallinckrodt” or the “Company”) (NYSE: MNK) securities between June 17, 2022 and June 14, 2023, inclusive (the “Class Period”). If you suffered a loss on your Mallinckrodt investments or would like to inquire about potentially pursu.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Mallinckrodt plc (MNK)

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming September 5, 2023 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Mallinckrodt plc (“Mallinckrodt” or the “Company”) (NYSE: MNK) securities between June 17, 2022 and June 14, 2023, inclusive (the “Class Period”). Investors suffering losses on their Mallinckrodt investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their le.

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Mallinckrodt plc (MNK)

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Mallinckrodt plc (“Mallinckrodt” or the “Company”) (NYSE: MNK) securities between June 17, 2022 and June 14, 2023, inclusive (the “Class Period”). Mallinckrodt investors have until September 5, 2023 to file a lead plaintiff motion. If you suffered a loss on your Malli.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Mallinckrodt plc (MNK) Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Mallinckrodt plc (“Mallinckrodt” or the “Company”) (NYSE: MNK) securities between June 17, 2022 and June 14, 2023, inclusive (the “Class Period”). Mallinckrodt investors have until September 5, 2023 to file a lead plaintiff motion. Investors suffering losses on their Mallinckrodt investments are encouraged to contact the Law Offices of Howard G.

News for Mallinckrodt PLC Stock (MNK)